Home/SOM Biotech/Silvia Panigone, Ph.D, MBA

SP

Silvia Panigone, Ph.D, MBA

CEO and Board Member

Therapeutic Areas

Neurology Psychiatry

SOM Biotech Pipeline

Drug	Indication	Phase
SOM3355	Huntington's disease	Phase 3
SOM1311	Phenylketonuria (PKU)	Preclinical
SOM3366	Tourette Syndrome	Preclinical
SOM0226	TTR Amyloidosis	Phase 2a PoC

Leadership Team at SOM Biotech

Rossella Medori, M.D

Chief Medical Officer

Kevin McAllister, Ph.D, MBA

Chief Scientific Officer

Oscar Huertas, M.Sc

Chief Technology Officer

View full SOM Biotech profile